GTC Biotherapeutics (fka GTCB)

[kayamalo1]

While it is generally true the being first matters a lot.
there are many exceptions. When the new drug is substantially better, it sells itself (with adequate marketing) For instance look how lucentis took share from macugen overnight. (or Zyprexa and Ablify in the psychopharm space) Better clinical results are more important to md's than sales rep's spin